RxDoctor Payments Data

Sandra Bond

Family · Jacksboro, TNNPI 1780185686

Payments from drug & device makers

$2,185in general payments, 2019–2025

Across 120 payments — averaging $18.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Harmony Biosciences LLC$724
  • AbbVie$538
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$260
  • Boston Scientific$163
  • Lilly USA, LLC$94
  • AstraZeneca$90
  • plus $316 from 10 others

What the payments were for

  • Food & beverage$2,185100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,185 in reported general payments places this provider in the 75th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$13,688
Medicare patients
57
Services billed
10,516

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide16$34,271
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$19,008
JardianceEmpagliflozin15$16,903
Nurtec OdtRimegepant Sulfate12$11,772
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$9,996
EliquisApixaban16$9,626
Albuterol Sulfate HfaAlbuterol Sulfate51$871
ProgesteroneProgesterone, Micronized30$733
Estradiol23$722
Esomeprazole Magnesium20$721
Omeprazole27$548
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen17$419
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst19$404
Levothyroxine Sodium61$363
Mirtazapine16$358

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$23$34,27116 claims
PfizerNurtec Odt, Eliquis$48$21,39828 claims
GSKTrelegy Ellipta$21$19,00822 claims
AstraZenecaBreztri Aerosphere$90$9,99616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,706 family providers in Tennessee.

Other family in Jacksboro

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →